GENETICS AND PROSTATE CANCER

VistaSeq® Germline Testing
VistaSeq®
Germline Testing

Hereditary cancer syndromes account for approximately 5-10% of all prostate cancers and are caused by inherited mutations (pathogenic variations) in certain genes. These inherited disorders increase the risk of developing cancer, often at an earlier age than expected. BRCA-related breast and ovarian cancer syndrome and Lynch syndrome are two syndromes known to be associated with a history of prostate cancer. In addition to susceptibility to prostate cancer, each of these conditions increase a person’s risk for other cancers.

The National Comprehensive Cancer Network Guidelines (NCCN Guidelines for Patients®) and recommendations

Patients diagnosed with Grade Group (GG) 1-3 prostate cancers and a suspicious family history should undergo germline testing, and those with GG 4 and 5 prostate cancers should be tested as well.

Patients who meet the criteria for hereditary cancer risk assessment should undergo germline genetic testing.

Why Test?

- It can identify patients with genetic mutations who are more likely than the general population to develop certain types of cancer.
- Testing enables personalized medical management based on the patient’s prostate cancer risk, as well as screening younger patients earlier and more frequently.
- Testing for prostate cancer patients may provide specific information about the patient’s risk of recurrence.
- In patients with prostate cancer, genetic testing can enable targeted medical and surgical treatment options.
- Encourages family members to undergo targeted genetic testing.
VistaSeq Prostate Panel

How Labcorp Can Help

Labcorp now offers a new VistaSeq panel for prostate cancer that identifies the genes ATM, BRCA1, BRCA2, CHEK2, HOXB13 (no CNVs), MLH1, MSH2, MSH6, PALB2, and PMS2.

The NCCN Guidelines note that multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.6

Every patient comes from a different background with a unique personal and family medical history. When evaluating a patient for hereditary cancer risk, the better test to choose is one that matches the needs of the patient based on the complete medical history.

Consider VistaSeq panel testing for your patients who meet NCCN hereditary cancer risk assessment criteria. This includes a personal or family history of one or more of the following6:

- A previously identified germline mutation in the family
- Metastatic or intraductal prostate cancer
- Any NCCN prostate cancer risk group and Ashkenazi Jewish ancestry
- Prostate cancer at any age and a close relative with breast cancer diagnosed ≤ 50 or ovarian cancer at any age.
- Three or more cancers such as prostate or breast cancer at any age
- Male breast cancer
- Exocrine pancreatic cancer

Broadening Your Patients’ Options

VistaSeq hereditary cancer panels are designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.
Labcorp provides expertise to your practice through genetic counseling services tailored to you and your patients.

With more than 25 years of experience, Labcorp offers the largest national commercial network of genetic counselors. We provide a broad range of counseling services, including hereditary cancer care.

Comprehensive genetic counseling includes:
- Genetic risk assessment, including a review of the patient’s personal and family medical histories and genetic test results
- Patient education about genetic risk factors and appropriate testing options
- Patient information and support for informed decision-making
- Coordinated patient care to assist you in offering the right test at the right time to the right patient

Our genetic counselors are available to support you in managing patients at risk for a hereditary cancer syndrome by explaining appropriate genetic testing options, discussing the implications of test results, and helping you and your patients make thoughtful genetic health care decisions.

Call 855-GC-CALLS (855-422-2557) to learn more about our exceptional services or visit: integratedgenetics.com/genetic-counseling

Additional Benefits:
- **Rapid results**
  Turnaround time of 2-3 weeks
- **Extensive managed care contracts**
  Help patients maximize their benefits
- **Convenient blood draws**
  Labcorp has a nationwide network of patient service centers, allowing easy access to sample collection. Visit www.Labcorp.com to find the nearest location.

### Test/Panel Name

<table>
<thead>
<tr>
<th>Test/Panel Name</th>
<th>Test No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>VistaSeq® Prostate Panel</td>
<td>483555</td>
</tr>
<tr>
<td>VistaSeq® Hereditary Cancer Panel</td>
<td>481220</td>
</tr>
<tr>
<td>VistaSeq® without BRCA1 and BRCA2 genes</td>
<td>481240</td>
</tr>
<tr>
<td>VistaSeq® Breast Cancer Panel</td>
<td>481319</td>
</tr>
<tr>
<td>VistaSeq® High/Moderate Risk Breast Cancer Panel</td>
<td>481452</td>
</tr>
<tr>
<td>VistaSeq® GYN Cancer Panel</td>
<td>481330</td>
</tr>
<tr>
<td>VistaSeq® Breast and GYN Cancer Panel</td>
<td>481341</td>
</tr>
<tr>
<td>Mutation-specific Sequencing</td>
<td>640/641</td>
</tr>
</tbody>
</table>

**Specimen requirements:**
- 10 mL whole blood lavender-top (EDTA) tube
- 2 mL saliva Oragene® or saliva collection kit

References

To learn more, visit Labcorp.com or contact your Labcorp representative.